UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for Primary Generalized Tonic-Clonic Seizures

 UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for Primary Generalized Tonic-Clonic Seizures

UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for for Primary Generalized Tonic-Clonic Seizures

Shots:

  • The EMA’s CHMP has adopted a positive opinion on a license extension for Vimpat (lacosamide) and Lacosamide UCB (lacosamide) as an adjunctive therapy in the treatment for PGTCS in adults, adolescents, and children from 4 years of age with idiopathic generalized epilepsy
  • The CHMP’s positive opinion is based on P-lll study assessing lacosamide as an adjunctive treatment for uncontrolled PGTCS. The therapy lowered the risk of developing a second PGTCS during a 24wks. period and demonstrated a higher rate of freedom from PGTCS during the treatment period
  • The company expects the EC’s formal approval decision before the end of 2020, that broaden the clinical application of Vimpat and make a new treatment option available to aid the management of PGTCS

Click here ­to­ read full press release/ article | Ref: UCB | Image: BioExcel

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post